Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0CL1D
|
|||
| Drug Name |
Dihydroisoxazole derivative 2
|
|||
| Synonyms |
PMID26560530-Compound-52
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
Leland Stanford Junior University
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H23BrFN5O4
|
|||
| Canonical SMILES |
C1C(ON=C1Br)CNC(=O)C(CC2=CNC3=C2C=C(C=C3)F)NC(=O)OCC4=CC5=CC=CC=C5N=C4
|
|||
| InChI |
1S/C26H23BrFN5O4/c27-24-10-19(37-33-24)13-31-25(34)23(8-17-12-30-22-6-5-18(28)9-20(17)22)32-26(35)36-14-15-7-16-3-1-2-4-21(16)29-11-15/h1-7,9,11-12,19,23,30H,8,10,13-14H2,(H,31,34)(H,32,35)/t19?,23-/m0/s1
|
|||
| InChIKey |
SUDBOOMQYSPULE-BVHINDKJSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue transglutaminase (TG2) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Tissue transglutaminase (TG2) | Target's Patent Info | [1] | |
| KEGG Pathway | Huntington's disease | |||
| Pathway Interaction Database | Beta1 integrin cell surface interactions | |||
| Thromboxane A2 receptor signaling | ||||
| Alpha9 beta1 integrin signaling events | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Transglutaminase inhibitors: a patent review.Expert Opin Ther Pat. 2016;26(1):49-63. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.